Analysts Set T2 Biosystems Inc (TTOO) Target Price at $5.70
T2 Biosystems Inc (NASDAQ:TTOO) has been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.70.
Several analysts have issued reports on TTOO shares. Zacks Investment Research raised shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Wednesday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of T2 Biosystems in a report on Thursday, January 25th. Finally, Goldman Sachs Group started coverage on shares of T2 Biosystems in a report on Monday, January 29th. They issued a “neutral” rating and a $5.20 price target on the stock.
Shares of T2 Biosystems (NASDAQ TTOO) traded up $1.28 during midday trading on Tuesday, hitting $6.36. 1,552,770 shares of the company’s stock traded hands, compared to its average volume of 237,779. T2 Biosystems has a 12 month low of $2.50 and a 12 month high of $6.99. The stock has a market capitalization of $227.85, a P/E ratio of -3.35 and a beta of 1.49. The company has a quick ratio of 5.28, a current ratio of 5.40 and a debt-to-equity ratio of 2.25.
WARNING: “Analysts Set T2 Biosystems Inc (TTOO) Target Price at $5.70” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/analysts-set-t2-biosystems-inc-ttoo-target-price-at-5-70/1907809.html.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.